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I mmune recovery uveitis (IRU) is apart of immune reconstitution
inflammatory syndrome, which is char-
acterized by worsening or unmasking of
opportunistic infections after quick
improvement of immune functions in
previously immunosuppressed patients.
Immune recovery uveitis (IRU) is most
common inpatientswithhuman immun-
odeficiency virus (HIV) (Kempen et al.
2006), but has also been reported in
HIV-negative patients. The most com-
mon pathogen associated with IRU is
cytomegalovirus (CMV). Clinical fea-
tures of IRU include anterior uveitis and
vitritis complicated by development of
cataract, epiretinal membranes and cys-
toid macular oedema (CME). Patients
with IRU had a 20-fold higher risk of
CME, which represents a major cause of
visual loss in HIV-infected patients
(Kempen et al. 2006). Treatment of
IRU-associated CME is challenging.
Mostly, corticosteroids in various
administration routes are used, but this
approach obviously includes a risk of
reactivation of infection.
We observed a beneficial effect of
aflibercept in patients in five consecu-
tive patients (seven affected eyes) with
IRU-induced CME.
Clinical data of included patients are
given in Table 1. Four patients were
HIV-positive, and all had previously
treated CMV retinitis. All had a low
nadir of their CD4 lymphocyte counts
(<20/mm3) before start of their antiretro-
viral therapy. One additional HIV-nega-
tive patient developed bilateral CMV
retinitis during the aplastic phase after
chemotherapy and stem cell transplant
for acute myeloid leukaemia. Intravitreal
bevacizumab was administered in four
patients (five eyes): without improvement
of CME in three and with transient
improvement in one patient. Aflibercept
was given as a single injection, and
decision to repeat the injection was based
on OCT findings. Patients were initially
followed every 4 weeks and gradually
the intervals between the examinations
were increased.
All treated eyes achieved a resolu-
tion of CME and demonstrated
improved visual acuity. Resolution of
CME was noted after a single afliber-
cept injection even in eyes with ineffec-
tive previous treatment modalities (six
eyes treated with various combinations
of periocular and systemic corticos-
teroids, acetazolamide, somatostatin
analogue octreotide and intravitreal
bevacizumab). In two patients receiv-
ing aflibercept shortly after onset of
CME, a long-term remission was
Table 1. Characteristics of patients with immune recovery uveitis after treated cytomegalovirus retinitis.
Gender and age
at
onset IRU
(HIV status)
Cause of
immune
suppression
Previous treatment
CME*
Affected
eye(s)
Duration CME
before aflibercept
administration
VA before
aflibercept
administration
Final
VA
in
decimals
Central macular
thickness before
aflibercept therapy
(µm)
Final central
macular thickness
(µm)
N of
aflibercept
injections
Follow-up
since start of
aflibercept
(weeks)
F, 48 years,
HIV–§
Acute myeloid
leukaemia,
stem cell
transplantation
Acetazolamide, oral
and periocular
corticosteroids,
octreotide,
intravitreal
bevacizumab
RE
LE
3 months
<4 weeks
0.5
0.5
1.0
1.0
453
736
244
276
18
3
224
228
M, 62 years,
HIV+
AIDS Acetazolamide, oral
corticosteroids,
intravitreal
bevacizumab
RE
LE
8 months
5 months
0.9
0.05
1.0
0.6
471
527
254
228
3
1
110
104
M, 50 years,
HIV+
AIDS Acetazolamide, oral
prednisone,
intravitreal
bevacizumab
RE < 4 weeks 0.7 1.2 578 313 6 124
M, 47 years,
HIV+
AIDS Acetazolamide, oral
nonsteroidal
anti-inflammatory
drugs, intravitreal
bevacizumab
LE 5 years 0.4 0.6 383 328 3 80
M, 45 years,
HIV+†
AIDS None‡ LE 4 months 0.7 0.9 371 239 2 24
AIDS = acquired immune deficiency syndrome; CME = cystoid macular oedema; HIV = human immunodeficiency virus; IRU = immune recovery
uveitis; OCT = ocular coherence tomography; VA = visual acuity.
* All affected eyes were treated by topical corticosteroid and nonsteroidal anti-inflammatory drops in various dosages.
† Other eye destroyed by extensive CMV retinitis.
‡ In this patient, we chose aflibercept as a consequence of earlier failure of other treatment options and success of aflibercept in other IRU patients.
§ HIV-negative patient developed bilateral CMV retinitis during the aplastic phase after chemotherapy and stem cell transplant for acute myeloid
leukaemia. This patient developed IRU four months after the activity of her CMV retinitis subsided and had at that time negative aqueous PCR
results for CMV.
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achieved, which did not require any
additional therapy.
The increased levels of intraocular
proangiogenic factors, such as vascular
endothelial growth factor (VEGF) and
placental growth factor (PlGF), were
repeatedly reported in ocular inflam-
mation (Kozak et al 2017). These
factors, next to their proangiogenic
activity, also activate endothelial cells
and promote cell proliferation, migra-
tion and vascular permeability. The
anti-inflammatory effect of intraocular
bevacizumab and aflibercept was pre-
viously documented (Papadopoulos
et al. 2012; Sato et al. 2018). Afliber-
cept has a markedly higher affinity for
VEGF-A than bevacizumab and rani-
bizumab, and moreover, aflibercept
binds VEGF-B and PlGF (Papadopou-
los et al. 2012). It is possible that these
differences are responsible for a better
effect of aflibercept in patients with
IRU-induced CME.
Several cases of HIV-infected
patients were described with previously
unrecognized CMV retinitis who devel-
oped symptoms of active CMV retinitis
together with active inflammatory signs
attributed to IRU shortly after the start
of antiretroviral treatment (Rangel
et al. 2015). Treatment modality with
aflibercept might be especially of value
in patients with uncertain activity of
CMV retinitis.
Our study has multiple shortcom-
ings. First, the number of patients is
very small, and patients were not
treated in systematic fashion. Despite
our limitations, we believe that consid-
eration should be given to the use of
intravitreal aflibercept in patients with
IRU, especially in those who have
failed other treatments.
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